𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

✍ Scribed by Kavanaugh, Arthur (author);Mease, Philip J. (author);Gomez-Reino, Juan J. (author);Adebajo, Adewale O. (author);Wollenhaupt, Jürgen (author);Gladman, Dafna D. (author);Lespessailles, Eric (author);Hall, Stephen (author);Hochfeld, Marla (author);Hu, Chiachi (author);Hough, Douglas (author);Stevens, Randall M. (author);Schett, Georg (author)

Book ID
126463931
Publisher
BMJ Publishing Group
Year
2014
Tongue
English
Weight
543 KB
Volume
73
Category
Article
ISSN
0003-4967

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of psoriatic arthritis in a ph
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
✍ Kavanaugh, Arthur (author);Mease, Philip J. (author);Gomez-Reino, Juan J. (autho 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 543 KB

## Objectives Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying anti